Direct compression of pharmaceutical-grade L-arginine base and L-arginine hydrochloride for oral solid dosage forms—supplied as L-Arginine amino acids and derivatives Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable—begins with salt selection because the base and hydrochloride differ in compressibility, chloride load, and moisture uptake. L-arginine base, CAS 74-79-3, exhibits pKa values of 2.17, 9.04, and 12.48; the hydrochloride salt, CAS 1119-34-2, increases aqueous solubility above 250 mg/mL and is generally less hygroscopic but adds chloride ion that must be controlled against the USP monograph limit. Formulation addition ratios for direct compression are typically 50–70% w/w L-arginine base or hydrochloride, 20–40% w/w microcrystalline cellulose PH 102, 2–5% w/w crospovidone, 0.5–1.5% w/w magnesium stearate, and 0.5–1.5% w/w colloidal silicon dioxide. On production-scale rotary tablet presses with 10-station tooling, precompression force is maintained at 3–5 kN and main compression force at 15–25 kN at turret speeds of 20–40 rpm; the target tablet hardness is 80–120 N, friability is controlled below 1.0%, and disintegration is specified as not more than 30 min under USP <701>. Unit weight and content uniformity are evaluated according to USP <905>, friability according to USP <1216>, and residual solvents according to USP <467> where isopropyl alcohol is used as a pre-granulation solvent. At relative humidity above 55% RH and 25°C, L-arginine base may deliquesce; core moisture is therefore held below 2.0% w/w before aqueous film coating. Batch-to-batch variability in particle size distribution is a known production bottleneck: when fines below 75 µm exceed 20% w/w, feed-frame segregation produces weight variation above 3.5% RSD, requiring dry granulation by slugging or roller compaction. Compliance is anchored to the USP L-Arginine monograph, Ph.Eur. 01/2008:1389, ICH Q3D elemental impurity limits, and 21 CFR 211 good manufacturing practice. Terminal dosage forms are 500 mg and 1000 mg film-coated tablets, and hard gelatin capsules size 00 or 000 filled to 500 mg or 1000 mg base equivalents.

Why Does Moisture Uptake Set the Granulation Window for Arginine Oral Powder and Effervescent Granule Lines?

Wet granulation of L-arginine base or L-arginine hydrochloride for single-dose oral granules and stick-pack powders is governed by the substance’s deliquescence above 55% RH and its acid-base reactivity in effervescent matrices. For non-effervescent oral granules, the addition ratio is 3.0–5.0 g L-arginine base per sachet, with mannitol 20–35% w/w, xylitol 10–20% w/w, povidone K30 1–3% w/w, and a flavor/sweetener system not exceeding 2–5% w/w. Effervescent granules use 3.0–5.0 g L-arginine base per dose, anhydrous citric acid 10–15% w/w, sodium bicarbonate 15–20% w/w, polyethylene glycol 6000 1–2% w/w, and an anhydrous ethanol granulation vehicle to prevent premature carbon dioxide release. The downstream process is top-spray fluid-bed granulation in 316L stainless steel equipment, with inlet air temperature 40–55°C, product temperature 28–35°C, air flow 60–120 m³/h, and final moisture 1.0–2.0% w/w. If product temperature exceeds 38°C, L-arginine base forms hard oversize agglomerates that require post-milling and increase the fraction below 125 µm, reducing flow and increasing stick-pack fill weight variability. Granules are milled to 125–500 µm, with bulk density controlled at 0.45–0.60 g/mL, and packaged in aluminum foil sachets under nitrogen or argon flush to maintain moisture below 2.0% w/w. Compliance for pharmaceutical-grade granules includes the USP L-Arginine monograph where applicable, USP <795> for compounding, USP <905> for dosage unit uniformity, ICH Q3D, and 21 CFR 111 dietary supplement GMP when the finished product is marketed as a supplement. Terminal dosage forms are 3 g and 5 g stick packs, effervescent granules in 20 mL to 200 mL reconstitution volumes, and bulk oral powder supplied to contract manufacturers for dose-in-sachet operations.

Parenteral nutrition amino acid injections incorporate L-arginine as a conditionally essential amino acid because surgical stress, sepsis, trauma, and critical illness increase endogenous arginine demand while enteral intake is absent. In a 10% crystalline amino acid injection, L-arginine is typically present at 4.0–7.0 g/L, corresponding to 4–7% of total amino acids on a weight basis; in 15% or 20% formulations, absolute concentration rises proportionally to 6.0–14.0 g/L while the ratio to total amino acids remains constant. The addition ratio must balance chloride load and pH stability: L-arginine hydrochloride contributes chloride and lowers pH, while L-arginine base requires adjustment with acetic acid to final pH 5.5–6.5. Downstream compounding uses high-purity water for injection in 316L stainless steel or borosilicate glass vessels, with nitrogen sparging to maintain dissolved oxygen below 0.1 mg/L because arginine is susceptible to Maillard-type degradation in the presence of reducing sugars. Dextrose solutions are therefore filled and sterilized separately before aseptic admixture. Terminal sterilization is achieved by autoclave at 121°C for 15 min for heat-tolerant containers, or by 0.22 µm aseptic filtration with subsequent aseptic filling for flexible bags. Injectable particulate matter is controlled under USP <788>, sterility under USP <71>, bacterial endotoxins under USP <85> with a limit below 0.5 EU/mL, and elemental impurities under ICH Q3D. Terminal dosage forms are 250 mL, 500 mL, and 1000 mL polypropylene or polyolefin infusion bags, and 100 mL glass vials used for central-line or peripheral parenteral nutrition admixture.

When Arginine Hydrochloride Is Formulated as an Intravenous Stimulation Agent in Endocrine Testing

L-arginine hydrochloride injection at 100 mg/mL (10% w/v) is manufactured as a diagnostic stimulus for pituitary growth hormone reserve in pediatric and adult endocrinology. The clinical dose is computed at 0.5 g/kg body weight, with a maximum of 30 g, infused intravenously over 30 min in 0.9% sodium chloride. For manufacturing, L-arginine hydrochloride is dissolved in water for injection to 100 mg/mL arginine hydrochloride, adjusted to pH 5.0–6.5 with hydrochloric acid or sodium hydroxide, and sparged with nitrogen before filling into 300 mL single-dose glass vials or 100 mL vials. Terminal sterilization at 121°C for 15 min is used; however, heat exposure above 121°C or prolonged cycles can increase related substances and must be monitored against the USP Arginine Hydrochloride Injection monograph and organic impurity limits. The formulation addition ratio is 100 mg/mL active, with water for injection q.s., and no buffering system, because unbuffered arginine hydrochloride solutions remain within acceptable pH drift over the labeled shelf life. Compliance includes USP <1>, USP <71>, USP <85>, USP <788>, 21 CFR 210/211, and ICH Q3D. Terminal dosage form is 30 g/300 mL single-dose vial for controlled intravenous infusion; in some markets, 10% L-arginine hydrochloride injection is supplied as 100 mL vials for institutional use. Infusion rate must be controlled because rapid administration can produce significant osmotic load; published data for specific pediatric dilution configurations is limited and requires institutional protocol verification.

In biopharmaceutical downstream formulation, L-arginine hydrochloride is added to high-concentration monoclonal antibody liquids as a preferential hydration and solubilizing agent to suppress aggregation and viscosity. The addition ratio is expressed in millimolar rather than weight percent; typical stabilizer concentrations range from 50 mM to 200 mM, corresponding to approximately 10.5–42 mg/mL L-arginine hydrochloride, while the monoclonal antibody concentration is 50–150 mg/mL and pH is maintained at 5.0–6.5 with histidine or acetate buffers. Manufacturing uses tangential flow filtration with 30 kDa molecular weight cutoff membranes for buffer exchange, addition of L-arginine hydrochloride to the diafiltration buffer, pH verification, and final 0.22 µm aseptic filtration into vials or prefilled syringes. Terminal dosage forms are 50 mg/mL, 100 mg/mL, or 150 mg/mL monoclonal antibody injections in 1 mL or 2.25 mL prefilled syringes, and 20 mL single-dose vials. Compliance for this application is governed by ICH Q8 pharmaceutical development, ICH Q6B specifications for biological products, USP <1043> ancillary material evaluation, USP <71>, USP <85>, and 21 CFR 211. Stability data for specific monoclonal antibody-arginine formulations are proprietary; published data for this specific configuration is limited to accelerated aggregation studies under 40°C/75% RH stress conditions, where arginine hydrochloride at 100–200 mM reduced aggregate formation relative to sodium chloride controls. At concentrations above 200 mM, stabilization is not universal: some antibody domains may show reduced thermodynamic stability, requiring candidate-specific screening before lock-in formulation.